Panbela Therapeutics is a clinical-stage biopharmaceutical company developing disruptive therapeutics for patients with urgent unmet medical needs. The objective of Panbela’s pipeline is the utilization of pharmacotherapies to reduce or normalize increased disease-associated polyamines using complementary pharmacotherapies. Their Polyamine Metabolic Inhibitor (PMI) drug targeting strategies may allow for product opportunities in therapeutic areas of high unmet medical need.
Location: United States, Minnesota, Waconia
Investors 1
| Date | Name | Website |
| - | Florida In... | florida-in... |
Mentions in press and media 7
| Date | Title | Description |
| 12.03.2024 | Panbela to Host Fourth Quarter and Year End 2023 Earnings Conference Call on March 26, 2024 | - |
| 12.03.2024 | Panbela to Host Fourth Quarter and Year End 2023 Earnings Conference Call on March 26, 2024 | MINNEAPOLIS, March 12, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), (“Panbela”), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announc... |
| 21.06.2023 | Panbela Announces Closing of Approximately $8.5 Million Public Offering | /EIN News/ -- MINNEAPOLIS, June 21, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announc... |
| 21.06.2023 | Panbela Announces Closing of Approximately $8.5 Million Public Offering | - |
| 16.06.2023 | Panbela Announces Pricing of Approximately $8.5 Million Public Offering | - |
| 04.10.2022 | ROTH Capital Partners to Host Inaugural Healthcare Opportunities Conference on October 6th at the Yale Club in New York City | Event to feature company presentations and one-on-one meetings between institutional investors and senior management from select Healthcare companies in Biotechnology, Pharmaceuticals, Medical Technologies, Oncology and Mental Health Therap... |
| 09.06.2021 | Panbela Therapeutics : Presentation | SBP-101, a Polyamine Metabolic Inhibitor, Administered in Combination with Gemcitabine and Nab-paclitaxel, shows Signals of Efficacy as First-Line Treatment for Subjects with Metastatic Pancreatic Ductal Adenocarcinoma ASCO 2021 Abstract 41... |